Granules India Q4 & FY26 Results: Standalone PAT up 25%, Revenue Grows 15%

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹703.00

prior close

₹711.60

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.5%-0.4% vs market

Pharmaceuticals peers, median of 165sector+0.0%+0.1% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+0.4

15m

+0.3

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+0.5-0.4+0.0+0.1

Next day

-0.3+0.1-0.3-0.5+0.2

-0.3+1.0-1.3+0.0-0.3

+1.6+1.2+0.4+0.5+1.1

+4.7+3.1+1.6+2.3+2.4

+5.7+4.1+1.6+3.0+2.7

+7.4+3.2+4.2+3.2+4.2

15d

+8.8+0.4+8.4+2.4+6.4

+10.7+1.6+9.1+3.8+6.8

+13.2+5.4+7.8+4.8+8.4

+19.9+7.5+12.4+7.1+12.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Granules India reported FY26 standalone revenue of Rs 3,474 cr, up 14.7% YoY, with profit after tax at Rs 401 cr, up 25.4% YoY. Consolidated revenue rose nearly 20% to Rs 5,366 cr with PAT of Rs 595 cr. Q4 standalone PAT was Rs 99 cr on revenue of Rs 877 cr. Board recommended final dividend of Rs 1.75/share. Acquisitions of Senn Chemicals AG and Granules Pharmaceuticals GmbH expanded group footprint. USFDA warning letter on Gagillapur facility was noted.

Likely market impact

Strong 25% PAT growth and acquisitions signal positive momentum; Rs 1.75 dividend rewards shareholders; USFDA overhang on Gagillapur remains a watchpoint.